Printer Friendly

IMMUNEX BEGINS SOLUBLE TNF RECEPTOR TRIALS; NIH LAUNCHES FIRST STUDY IN SEPSIS PATIENTS

 IMMUNEX BEGINS SOLUBLE TNF RECEPTOR TRIALS;
 NIH LAUNCHES FIRST STUDY IN SEPSIS PATIENTS
 SEATTLE, July 20 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) announced the start of Phase I clinical trials of soluble Tumor Necrosis Factor (TNF) receptor for the treatment of sepsis. The initial Phase I study, which is being conducted at the National Institutes of Health (NIH) in Bethesda, Md., will test the ability of soluble TNF receptor to block systemic inflammation caused by bacterial infection.
 Sepsis is a systemic inflammatory response to infection triggered by the release of immune system proteins such as TNF. According to the National Center for Health Statistics, approximately 500,000 patients experience sepsis each year in the United States. Half of these patients progress to septic shock, which can result in organ failure and death.
 Studies published in the September 1991 issues of "Annals of Internal Medicine" and "The Lancet" indicate that TNF is the central mediator of sepsis. A May 1992 study published in the journal "Immunology" reported a positive correlation between naturally occurring TNF receptor blood levels and survival in patients with bacterial infection. Immunex scientists believe that soluble TNF receptor may represent a potential treatment for systemic inflammation arising from gram-negative or gram-positive bacterial infections or fungal infections. The Phase I human clinical trial, conducted by NIH Clinical Center researcher Anthony Suffredini, M.D., will investigate the biological activity of soluble TNF receptor in healthy patients who receive a safe dose of lipopolysaccharide (LPS), a component of gram-negative bacteria.
 At the April 1992 meeting of the Federation of American Societies for Experimental Biology (FASEB), Immunex scientists presented data from a study of LPS-induced septic shock in mice in which soluble TNF receptor reduced mortality by 90 percent as compared to placebo controls. These data indicated that soluble TNF receptor can effectively block the inflammation that leads to septic shock.
 "Soluble receptors may be useful in regulating inflammatory diseases such as sepsis by shutting down the development or progression of the disease," said Immunex Executive Vice President Steven Gillis, Ph.D. "We plan to pursue receptor products in a wide range of autoimmune and inflammatory conditions."
 The soluble TNF receptor is the second receptor product to enter clinical study. Immunex is currently conducting Phase I clinical trials of its soluble Interleukin-1 (IL-1) receptor in allergy, rheumatoid arthritis, graft versus host disease and septic shock. Additional studies are planned to begin later this year for the treatment of chronic myelogenous leukemia.
 Soluble receptors may be capable of turning off specific immune responses in a broad spectrum of autoimmune and inflammatory diseases by preventing immune system proteins called cytokines from binding to cell-surface receptors and signaling a reaction. Immunex scientists have used recombinant DNA technology to produce soluble versions of naturally occurring cytokine receptors that intercept and inactivate these proteins.
 Immunex licensed U.S. rights for its receptor products to Receptech Corp. (NASDAQ: RECP), which was formed by Immunex in 1989 to fund receptor development. Receptech is developing products to treat conditions such as allergy, asthma, arthritis, cachexia and septic shock. Immunex has an option to license or buy back Receptech products for cash or exchange of common stock.
 Immunex is a biopharmaceutical company focused on the research, development, manufacture and marketing of products to treat cancer and autoimmune disease.
 -0- 7/20/92
 /CONTACT: Jason Rubin or Mary McConnon of Immunex, 206-587-0430/
 (RECP IMNX) CO: Immunex Corp.; Receptech Corp. ST: Washington IN: MTC SU:


SC -- SE002 -- 0623 07/20/92 10:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:580
Previous Article:COMPUTER LANGUAGE RESEARCH REPORTS SECOND QUARTER 1992 RESULTS OF OPERATIONS AND CASH DIVIDEND DECLARATION
Next Article:E-Z SERVE CORPORATION TO ACQUIRE TOC RETAIL
Topics:


Related Articles
IMMUNEX IL-1 RECEPTOR CLINICAL TRIALS BEGIN; FIRST STEP IN AGGRESSIVE CLINICAL RESEARCH PROGRAM
/C O R R E C T I O N -- IMMUNEX/ (Correction Notice)
T CELL SCIENCES COMPLETES PHASE 1 CLINICAL TRIAL WITH TP10 IN ARDS
PIXYKINE PHASE III RESULTS IN TRANSPLANTATION SHOW BENEFIT SIMILAR TO CONTROL DRUG LEUKINE
Immunex Arthritis Drug Shown Safe With Additional Data
ENBREL(TM) Study Published Today Shows RA Patients' Symptoms Improve
Immunex Announces Results of Pivotal Trial for ENBREL in Rheumatoid Arthritis, Confirming Effectiveness
INMUNEX: New Approach to Rheumatoid Arthritis
New Data on Immunex's Leukine Presented at 12th World AIDS Conference; Reduction in Viral Load Reported in AIDS Patients
FDA Advisory Committee Will Review Enbrel(TM) for Potential Use in Active Rheumatoid Arthritis

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters